Atezolizumab Plus nab-Paclitaxel in the Treatment of Metastatic Triple-Negative Breast Cancer With 2-Year Survival Follow-up

Adams, Sylvia; R. Diamond, Jennifer; Hamilton, Erika; R. Pohlmann, Paula; M. Tolaney, Sara; Chang, Ching‐Wei; Zhang, Wei; Iizuka, Koho; Foster, Paul; Molinero, Luciana; Funke, Roel; D. Powderly, John

doi:10.1001/jamaoncol.2018.5152

Public

Atezolizumab Plus nab-Paclitaxel in the Treatment of Metastatic Triple-Negative Breast Cancer With 2-Year Survival Follow-up

Published in JAMA Oncology • Oct 22, 2018

Authors:

Sylvia Adams

Jennifer R. Diamond

Erika Hamilton

Abstract

Importance: The humanized monoclonal antibody atezolizumab targets programmed death-ligand 1 and has demonstrated durable single-agent activity in a subset of metastatic triple-negative breast cancers. To extend the observed activity, combinatorial approaches are being tested with standard cytotoxic...

Subject

Medicine

Atezolizumab

Tolerability

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!